Epic Bio to Participate in Upcoming Investor Conference
07 nov. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
26 oct. 2023 11h09 HE
|
Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
17 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase
05 oct. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Global Epigenomics Market Research Report 2023-2031 Featuring Epigenomics AG, Illumina, Merck, Zymo Research, & Agilent Technologies
03 oct. 2023 07h03 HE
|
Research and Markets
Dublin, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The "Global Epigenomics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global epigenomics market...
Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society
28 sept. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
19 sept. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
14 sept. 2023 12h00 HE
|
Epic Bio
- Vast high-throughput screening study used to train unique machine learning algorithm to design synthetic activators - - Rational engineering produced activators that induce the most...
Global Epigenetic Therapeutics Market to Reach $9.8 Billion by 2028 - Projected Revenue Shares for PRAP, Kinase, IDH, HDAC, DNMT, and KMT Inhibitors
23 juin 2023 05h08 HE
|
Research and Markets
Dublin, June 23, 2023 (GLOBE NEWSWIRE) -- The "Epigenetic Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global epigenetic therapeutics market was...